Table 2.
Platelet performances as measured by CCI1h and CCI24h per patient group
| Acute leukemiaa |
NHLb |
HL |
MDS |
Marrow aplasiac |
MM |
Non-hematologicald |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CCI1h | CCI24h | CCI1h | CCI24h | CCI1h | CCI24h | CCI1h | CCI24h | CCI1h | CCI24h | CCI1h | CCI24h | CCI1h | CCI24h | |
| Number of platelet products transfused | 8 | 52 | 5 | 28 | 4 | 9 | 0 | 15 | 3 | 3 | 2 | 9 | 1 | 4 |
| Mean (SD) | 9,262 | 3,282 | 7,592 | 5,920 | 7,288 | 1,544 | 5,030 | 10,828 | 4,815 | 9,560 | 8,800 | 6,409 | 13,200 | |
| (6,248) | (3,355) | (1,065) | (7,250) | (2,885) | (3,170) | (6,500) | (2,968) | (3,038) | (8,810) | (3,897) | (6,979) | |||
| Median (range) | 8,403 | 3,445 | 8,600 | 4,240 | 8,250 | 494 | 2,100 | 9,270 | 3,880 | 9,560 | 7,110 | 15,235 | ||
| (0–17,960) | (–3,500 | (3,000– | (–3,330– | (3,150– | (–1,777– | (–2,490– | (8,960– | (3,033– | (3,330– | (1,770– | (3,662– | |||
| to 5,800) | 3,510) | 3,1350) | 9,500) | 8,900) | 16,540) | 14,250) | 8,300) | 15,970) | 16,308) | 18,020) | ||||
HL = Hodgkin's lymphoma; MDS = myelodysplastic syndrome; MM = multiple myeloma; NHL = non-Hodgkin's lymphoma.
a
Acute leukemia, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
b
NHL, including B-cell lymphoma.
c
Marrow aplasia, including aplasia and hypoplasia.
d
Non-hematological, including post-cardiac surgery and liver cirrhosis.